Pyros Pharmaceuticals | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

8,937 results for “Pyros Pharmaceuticals”

Trials

View all 575 →

Steady State Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets

First posted Jul 6, 2012

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets Under Fed Conditions

First posted Jul 6, 2012

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets Under Fasting Conditions

First posted Jul 6, 2012

Drugs

View all 1724 →

Romiplostim biosimilar (Intas Pharmaceuticals)

factor VIII nanoparticle (Zoetic Pharmaceuticals)

delta opioid agonists/mu opioid antagonists (Dina Pharmaceuticals)

Organizations

View all 2043 →

Pyros Pharmaceuticals, Inc.

United States

Syros Pharmaceuticals

United States

MILESTONE PHARMACEUTICALS

India

News

View all 4595 →

Bora Pharmaceuticals Acquires Pyros Pharmaceuticals, Expanding Rare Disease Portfolio

Syros Pharmaceuticals Announces SELECT-MDS-1 Trial Update and Strategic Realignment

Syros Pharmaceuticals Advances Clinical Programs in MDS, AML, and APL

Page 1 of 894